Revised 16 September 2026 · v1.1.0 · what changed

Sun Pharma's board signed a definitive agreement on 27 April 2026 to acquire Organon & Co., the New Jersey-based women's-health and biosimilars company Merck spun off in 2021, in an all-cash deal worth $11.75 billion — $14.00 a share, including Organon's existing debt. It is the largest outbound acquisition any Indian pharmaceutical company has attempted, and unusually for a corporate deal this blog would normally leave to the financial press, its financing runs straight into the same RBI overseas-borrowing framework this blog has covered before: the deal needs more headroom than even February 2026's liberalisation of that framework provides.

The Reserve Bank of India's Mumbai headquarters. The RBI's overseas-direct-investment guarantee framework, and the special dispensation it granted, sit at the center of how Sun Pharma financed the Organon deal. Source: Pinakpani, Wikimedia Commons, CC BY-SA 4.0.

1. What Sun Pharma is actually buying

Organon reported $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for the year ended December 2025. Combined with Sun Pharma's own book, the deal lifts group revenue to roughly $12.4 billion, pushing Sun Pharma into the top 25 global pharmaceutical companies by that measure, into the top 3 globally in women's health, and into the world's 7th-largest biosimilar company by Organon's existing portfolio. The combined group would have a footprint across 150 countries, including 18 markets each generating more than $100 million in revenue on their own. Dilip Shanghvi, Sun Pharma's executive chairman, named two specific strategic gains beyond scale: entry into the Chinese market, and a foothold in biosimilars that Sun had deliberately avoided building organically until India's own rules on biosimilar substitution and pharmacy-level interchangeability became clear enough to act on.

2. The financing problem this piece actually cares about

Sun Pharma plans to fund the purchase through a mix of cash on hand and committed bank financing, reportedly including $3–4 billion in offshore loans, a possible euro-denominated bond (which could carry a rating one to two notches above Organon's own pre-deal rating), and a consent solicitation asking Organon's existing bondholders to swap into Sun Pharma debt instead. State Bank of India has reportedly proposed committing up to $1 billion to the syndicate, subject to its own board approval — a notable detail on its own, since a domestic public-sector bank taking a meaningful slice of an outbound Indian takeover's financing is still unusual.

The regulatory wrinkle sits underneath all of that. This blog's earlier coverage of India's fuel-to-chemicals financing wave noted the RBI's February 2026 liberalisation of the External Commercial Borrowings framework, which raised the automatic-route ceiling to the higher of $1 billion outstanding or 300% of net worth and removed the all-in-cost ceiling entirely — a materially wider pipe than Indian companies borrowed through even two years earlier. The Organon deal's roughly $8 billion in financing and refinancing needs is reported to exceed even that widened ceiling once foreign-lender guarantees are counted against India's Overseas Direct Investment rules, which cap such guarantees at $1 billion before requiring specific RBI dispensation rather than automatic-route clearance. In other words: the same rule change built to make exactly this kind of outbound acquisition easier to finance was not, on its own, big enough for this specific deal — Sun Pharma needed RBI to grant an exception on top of the widened default rule.

Update, since first published: that dispensation cleared. Sun Pharma completed syndication of the debt financing on 30 June 2026 — eleven banks, SBI plus ten international lenders, each committing roughly $1 billion, together exceeding $10 billion in total debt financing. Organon's shareholders separately approved the merger in July 2026. Both the RBI-dependent financing and the target-company approval this piece flagged as open are now resolved; the deal's own timeline still targets an early-2027 close, subject to remaining customary regulatory conditions.

3. Why credit-rating agencies reacted well anyway

Despite the size and structure of the financing, both Moody's and S&P reportedly moved to a more favourable ratings stance on Sun Pharma over the announced bid — a signal that agencies read the deal's cash flow generation and Sun Pharma's balance-sheet capacity as adequate to the debt being raised, even before the RBI dispensation question is settled. That is a real data point in the deal's favour, distinct from the debate over whether the entry multiple itself was cheap.

4. What this signals beyond one company

Coverage of the deal has repeatedly framed it as a "turning point" for Indian pharma: a shift from Indian companies being reliable low-cost manufacturers for global majors toward acting as global consolidators in their own right, buying scale, geography and therapeutic-area leadership rather than only building it domestically. Whether that reading holds depends partly on whether other large Indian pharma companies follow with outbound deals of comparable size — and partly on whether India's outbound-financing plumbing, including the RBI dispensation this specific deal is testing, proves it can actually clear a deal this large without friction. A rule written in February to widen the pipe and a deal in April that turns out to still need an exception to it is, at minimum, a sign the pipe was sized for the deals policymakers expected, not necessarily the ones that show up first.

Sources: CNBC, Bloomberg and Organon's own press release on the deal announcement, terms and expected close date; Fierce Pharma, C&EN and GenEngNews on the strategic rationale and Dilip Shanghvi's statements; Forbes India and Outlook Business on valuation multiples and analyst reaction (Evercore ISI, AltG Investment Research Lab); Business Standard, Bloomberg and Outlook Business on the financing structure, the $8bn refinancing requirement, the RBI ODI $1bn guarantee-limit issue, and SBI's reported $1bn commitment; Outlook Business on the Moody's/S&P ratings response; Sun Pharma's own 30 June 2026 press release on the completed financing syndication and gabionline.net's report on the eleven-bank consortium, for the update on the financing/shareholder-approval status. This blog's own "Financing the Fuel-to-Chemicals Pivot," whose account of the RBI's February 2026 ECB liberalisation is reused directly for context, not re-derived. Unlike this blog's usual sourcing for policy pieces, no PIB or other government release was found discussing this deal directly, consistent with it being a private, NYSE-listed company's transaction rather than a state action.

Related on this blog

See also: Financing the Fuel-to-Chemicals Pivot · Dr. Reddy's Cut Its Semaglutide Guidance in Half After an API Impurity It Caught Itself · India Cannot Sell “China-Free” Medicine While Importing 43% of What's In It.

About this article: Researched, written and edited by Umashankar Triplicane Dwarakanathan, with AI research assistance; every figure is meant to trace to the primary source cited. See the Editorial Policy for how sourcing, AI use and corrections work.